CO4900057A1 - Dihidrato d de olanzapina - Google Patents
Dihidrato d de olanzapinaInfo
- Publication number
- CO4900057A1 CO4900057A1 CO97055058A CO97055058A CO4900057A1 CO 4900057 A1 CO4900057 A1 CO 4900057A1 CO 97055058 A CO97055058 A CO 97055058A CO 97055058 A CO97055058 A CO 97055058A CO 4900057 A1 CO4900057 A1 CO 4900057A1
- Authority
- CO
- Colombia
- Prior art keywords
- methyl
- olanzapine
- dihydrate
- olanzapine dihydrate
- benzodiazepine
- Prior art date
Links
- FUOBHGGXKJHKDF-UHFFFAOYSA-N 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine dihydrate Chemical compound O.O.C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 FUOBHGGXKJHKDF-UHFFFAOYSA-N 0.000 title 1
- -1 2-methyl-4- (4-methyl-d1-piperazinyl) -10H-thieno [2,3-b] [1,5] benzodiazepine Chemical compound 0.000 abstract 1
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 150000004683 dihydrates Chemical class 0.000 abstract 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 abstract 1
- 229960005017 olanzapine Drugs 0.000 abstract 1
- 239000007921 spray Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2648696P | 1996-09-23 | 1996-09-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4900057A1 true CO4900057A1 (es) | 2000-03-27 |
Family
ID=21832112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO97055058A CO4900057A1 (es) | 1996-09-23 | 1997-09-22 | Dihidrato d de olanzapina |
Country Status (34)
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA978515B (en) * | 1996-09-23 | 1999-03-23 | Lilly Co Eli | Intermediates and process for preparing olanzapine |
| US6617321B2 (en) | 1997-09-30 | 2003-09-09 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine formulation |
| HU227400B1 (en) * | 1998-09-30 | 2011-05-30 | Lilly Co Eli | 2-methyl-thieno-benzodiazepine formulation and its use |
| US7022698B2 (en) | 1999-12-28 | 2006-04-04 | U & I Pharmaceuticals, Ltd. | Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof |
| DK1246827T3 (da) * | 1999-12-28 | 2005-05-23 | Cipla Ltd | Nye polymorfe former af olanzapin |
| BR0114031A (pt) * | 2000-08-31 | 2003-09-09 | Reddy S Lab Ltd | Processo para a preparação de hidratos de olanzapina e sua conversão em formas cristalinas de olanzapina |
| US6740753B2 (en) | 2001-01-04 | 2004-05-25 | Geneva Pharmaceuticals, Inc. | Olanzapine crystal modification |
| AU2002340328A1 (en) * | 2001-10-29 | 2003-05-12 | Janet I. Cord | Olanzapine dihydrate-ii a process for its preparation and use thereof |
| DE60336226D1 (de) * | 2002-05-31 | 2011-04-14 | Sandoz Ag | Verfahren zur herstellung von olanzapin form i |
| SI21270A (sl) | 2002-07-15 | 2004-02-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Kristalne oblike olanzapina in postopki za njihovo pripravo |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| EP1575962A1 (en) * | 2002-12-24 | 2005-09-21 | Teva Pharmaceutical Industries Limited | Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms |
| US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| AU2004291043A1 (en) * | 2003-11-18 | 2005-06-02 | 3M Innovative Properties Company | Olanzapine containing transdermal drug delivery compositions |
| WO2005070938A1 (en) | 2004-01-27 | 2005-08-04 | Synthon B.V. | Stable salts of olanzapine |
| DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004030502A1 (de) | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel |
| DE102004033670A1 (de) | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
| EP1781666A1 (en) * | 2004-07-14 | 2007-05-09 | Shasun Chemicals and Drugs Limited | Improved process for making form i of olanzapine. |
| US20060074088A1 (en) | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| US7759485B2 (en) | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US7728134B2 (en) | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| EP1630163A1 (de) | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| ES2303462B1 (es) | 2004-09-06 | 2009-06-05 | Shasun Chemicals And Drugs Limited | Nuevo procedimiento para la preparacion de una forma polimorfica i de olanzapina farmaceuticamente pura. |
| BRPI0515946A (pt) | 2004-09-29 | 2008-08-12 | Bayer Healthcare Ag | sal de tosilato, sua preparação e uso, bem como composição farmacêutica compreendendo o mesmo |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| EA200701065A1 (ru) * | 2004-11-16 | 2007-12-28 | Элан Фарма Интернэшнл Лтд. | Инъецируемые составы, содержащие нанодисперсный оланзапин |
| DE102004058337A1 (de) | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
| EP1838716B1 (en) | 2005-01-05 | 2011-06-01 | Eli Lilly And Company | Olanzapine pamoate dihydrate |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| US8551986B2 (en) * | 2005-12-08 | 2013-10-08 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
| US7834176B2 (en) * | 2006-01-26 | 2010-11-16 | Sandoz Ag | Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| SG174054A1 (en) | 2006-05-04 | 2011-09-29 | Boehringer Ingelheim Int | Polymorphs |
| AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| US7718649B1 (en) | 2006-11-10 | 2010-05-18 | Pisgah Labs, Inc. | Physical states of a pharmaceutical drug substance |
| US8039461B1 (en) | 2006-11-10 | 2011-10-18 | Pisgah Laboratories, Inc. | Physical states of a pharmaceutical drug substance |
| EP2185559A1 (en) | 2007-08-03 | 2010-05-19 | Boehringer Ingelheim International GmbH | Crystalline form of a dihydropteridione derivative |
| US8883863B1 (en) | 2008-04-03 | 2014-11-11 | Pisgah Laboratories, Inc. | Safety of psuedoephedrine drug products |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| CN102036654B (zh) * | 2008-07-24 | 2014-05-14 | 湖南洞庭药业股份有限公司 | 稳定的非典型抗精神病制剂 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
| RU2011113823A (ru) | 2008-09-10 | 2012-10-20 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | Комбинированная терапия, предназначенная для лечения диабета и связанных с ним состояний |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| EP2382216A1 (en) | 2008-12-23 | 2011-11-02 | Boehringer Ingelheim International GmbH | Salt forms of organic compound |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| EP3646859A1 (en) | 2009-11-27 | 2020-05-06 | Boehringer Ingelheim International GmbH | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| NZ602921A (en) | 2010-05-05 | 2016-01-29 | Boehringer Ingelheim Int | Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor |
| KR20230051307A (ko) | 2010-06-24 | 2023-04-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
| AU2012285904C1 (en) | 2011-07-15 | 2017-08-31 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| EP4151218A1 (en) | 2012-05-14 | 2023-03-22 | Boehringer Ingelheim International GmbH | Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| EP2919788A4 (en) | 2012-11-14 | 2016-05-25 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA |
| JP2016027003A (ja) * | 2012-11-20 | 2016-02-18 | 大蔵製薬株式会社 | 長期間安定なオランザピンの水性医薬製剤 |
| JP2016525532A (ja) | 2013-07-26 | 2016-08-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 骨髄異形成症候群の処置 |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
| EP3468562A1 (en) | 2016-06-10 | 2019-04-17 | Boehringer Ingelheim International GmbH | Combinations of linagliptin and metformin |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5302716A (en) * | 1986-01-16 | 1994-04-12 | Schering Corporation | Fused benzazepines |
| US5229382A (en) * | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| GB9009229D0 (en) * | 1990-04-25 | 1990-06-20 | Lilly Industries Ltd | Pharmaceutical compounds |
| EP0582368B1 (en) * | 1992-05-29 | 2001-01-24 | Eli Lilly And Company Limited | Thienobenzodiazepine derivatives for treatment of CNS disorders |
| AU699134B2 (en) | 1994-06-28 | 1998-11-26 | Cryovac, Inc. | Bag having protective patches |
| IL117612A0 (en) * | 1995-03-24 | 1996-07-23 | Lilly Co Eli | Granule formulation for olanzapine |
| EG24221A (en) * | 1995-03-24 | 2008-11-10 | Lilly Co Eli | Process for preparing olanzapine |
| EG23659A (en) * | 1995-03-24 | 2007-03-26 | Lilly Co Eli | Process and crystal forms of methyl-thieno-benzodiazepine |
| US5631250A (en) * | 1995-03-24 | 1997-05-20 | Eli Lilly And Company | Process and solvate of 2-methyl-thieno-benzodiazepine |
-
1997
- 1997-09-18 HU HU0000065A patent/HU226167B1/hu not_active IP Right Cessation
- 1997-09-18 BR BR9711541A patent/BR9711541A/pt not_active IP Right Cessation
- 1997-09-18 ID IDW990059A patent/ID21924A/id unknown
- 1997-09-18 CN CNB971981213A patent/CN1146567C/zh not_active Expired - Fee Related
- 1997-09-18 CA CA002266444A patent/CA2266444C/en not_active Expired - Fee Related
- 1997-09-18 WO PCT/US1997/016586 patent/WO1998011893A1/en not_active Ceased
- 1997-09-18 KR KR10-1999-7002423A patent/KR100516088B1/ko not_active Expired - Fee Related
- 1997-09-18 AU AU44241/97A patent/AU720366B2/en not_active Ceased
- 1997-09-18 IL IL12895697A patent/IL128956A0/xx not_active IP Right Cessation
- 1997-09-18 PL PL97332541A patent/PL194074B1/pl unknown
- 1997-09-18 UA UA99031634A patent/UA56184C2/uk unknown
- 1997-09-18 TR TR1999/00639T patent/TR199900639T2/xx unknown
- 1997-09-18 NZ NZ334346A patent/NZ334346A/en not_active IP Right Cessation
- 1997-09-18 EA EA199900325A patent/EA001881B1/ru not_active IP Right Cessation
- 1997-09-18 JP JP10514881A patent/JP2001500878A/ja not_active Withdrawn
- 1997-09-18 CZ CZ0098999A patent/CZ299247B6/cs not_active IP Right Cessation
- 1997-09-18 RS YUP-154/99A patent/RS49597B/sr unknown
- 1997-09-22 SI SI9730408T patent/SI0831097T1/xx unknown
- 1997-09-22 CO CO97055058A patent/CO4900057A1/es unknown
- 1997-09-22 AT AT97307379T patent/ATE221074T1/de active
- 1997-09-22 SV SV1997000079A patent/SV1997000079A/es active IP Right Grant
- 1997-09-22 ES ES97307379T patent/ES2180899T3/es not_active Expired - Lifetime
- 1997-09-22 DK DK97307379T patent/DK0831097T3/da active
- 1997-09-22 ZA ZA978512A patent/ZA978512B/xx unknown
- 1997-09-22 DE DE69714165T patent/DE69714165T2/de not_active Expired - Lifetime
- 1997-09-22 EP EP97307379A patent/EP0831097B1/en not_active Expired - Lifetime
- 1997-09-22 MY MYPI97004393A patent/MY125467A/en unknown
- 1997-09-22 PT PT97307379T patent/PT831097E/pt unknown
- 1997-09-23 PE PE1997000853A patent/PE110298A1/es not_active Application Discontinuation
- 1997-09-23 EG EG98597A patent/EG23815A/xx active
- 1997-09-23 AR ARP970104361A patent/AR009801A1/es not_active Application Discontinuation
- 1997-09-23 US US08/935,883 patent/US6251895B1/en not_active Expired - Fee Related
-
1998
- 1998-02-27 TW TW086113833A patent/TW518335B/zh not_active IP Right Cessation
-
1999
- 1999-03-19 NO NO19991339A patent/NO323979B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4900057A1 (es) | Dihidrato d de olanzapina | |
| FI962155L (fi) | Uudet 9-hydroksipyrido (1,2-a) pyrimidin-4-onieetterijohdannaiset | |
| ES2159346T3 (es) | Formas cristalinas de un derivado de tieno(2,3-b)(1,5)benzodiazepina y procedimiento para su preparacion. | |
| IS4147A (is) | Aðferð til framleiðslu á 1,5 Benzodiazepine afleiðum | |
| ES2158327T3 (es) | Derivados de benzo(g)quinolina. | |
| AU4415285A (en) | Benzodiazepine derivatives | |
| DE59101477D1 (de) | Thieno[2,3-d]pyrimidinderivate. | |
| FI953794L (fi) | N-Alkyyli-2-substituoidut ATP-analogit | |
| FI971609L (fi) | Menetelmä 4a,5,9,10,11,12-heksahydro-6H-bentsofuro-(3a,3,2-ef)(2)-bentsatsepiinijohdannaisten valmistamiseksi | |
| SI1513846T1 (sl) | Postopek za pripravo olanzapina form I | |
| DK0733634T3 (da) | Fremgangsmåde til fremstilling af et thieno(2,3-b) (1,5)benzodiazepinderivat | |
| AU1373097A (en) | New phospholipid derivatives of phosphonocarboxylic acids, the production thereof as well as their use as antiviral pharmaceutical agents | |
| NO982843D0 (no) | 2,7-Substituerte oktahydro-pyrrol£1,2-a|pyrazin-derivater | |
| ES2152379T3 (es) | Dihidropiridinas condensadas y su utilizacion para la produccion de preparados farmaceuticos. | |
| GR1002883B (el) | Νεα παραγωγα της 2, 3-βενζοδιαζεπινης | |
| ES2160308T3 (es) | Nuevos derivados amino-metil-heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| ZA985211B (en) | Benzo (5,6) cycloheptapyridine compounds useful as farnesyl protein transferase inhibitors | |
| SI1513845T2 (sl) | Postopek za pripravo olanzapina in intermediat zanj | |
| FI973644L (fi) | Uusi menetelmä 2,3-dihydrobentsofuranolijohdannaisten valmistamiseksi | |
| ITTO910353A1 (it) | Composti triciclici, procedimento per la loro preparazione | |
| FI943999A7 (fi) | Pyrido(1,2,3-d,e)(1,3,4)bentsoksadiatsiinijohdannaisia | |
| DE69707293D1 (de) | Pyrrolo(3,2-c)chinolin-derivate | |
| FI940607A7 (fi) | Imidatso(5,1-C)(1,4)bentsoksatsin-1-onijohdannaiset 5HT3-antagonisteina | |
| HUP0003046A3 (en) | Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives for the inhibition of farnesyl protein transferase | |
| ES2159742T3 (es) | Procedimiento para la sintesis de benzo(b)tiofenos. |